Method for the prevention and treatment of leukemia in cattle

 

The invention relates to veterinary medicine. The method comprises the administration of a medicinal product, in addition enter iodized table salt, as well as drug use metronidazole while metronidazole and iodized table salt is administered courses once a day for 30 days every 6 months. In addition, prophylactic introduction animals metronidazole and iodized salt operate from 6 months to 18 months of age in the following doses, g/bird.: metronidazole 0,25; 0,5 and 1,0; iodized salt 30,0; and 50,0 70,0; and 12 months of age animals impose additional sulfa drug doses, respectively, 0.5 and 1.0 mg/goal. In addition, in this method with curative intent metronidazole is administered at a dose of 1.0 g/bird., and iodized table salt at a dose of 70-90 g/bird., in addition impose a sulfa drug at the dose of 1.0 g/bird. Repeat the treatment within 2 years. The method is highly effective in the treatment and prevention of leukemia using drugs antibacterial action against the elimination of iodine deficiency with concurrent prophylactic treatment of young animals with the purpose of recovery of the entire herd. 3 C.p. f-l is tion and prevention of leukemia in cattle (cattle).

Currently known development of the all-Russian Institute of experimental veterinary medicine (VIEV) against leukemia cattle, based on the viral nature of leukemia cattle, aimed at developing Wellness and preventive measures to combat leukemia cattle.

Based Wellness activities based on the principle of dividing the herd into two distinct groups: HIV infection (the virus leukemia cattle) and seronegative (no leukosis virus of cattle), and the supervision of these groups within 1.5-2 years in quarterly serological study and the destruction of newly identified infected animals, and the cultivation of healthy youngsters taking into account the main features of this disease is the lack of genetic transmission of the pathogen leukemia and, consequently, the possibility of rearing healthy calves isolated content heifers from patients and infected cows until the age of heifers and picking them safe from leukemia herds (See. "Veterinary newspaper. - 8. - 2001. - S. 4-5).

In addition, this Institute has developed a vaccine for immunization of leukemia cattle. The vaccine obtained with the use of vaccinia virus and the vaccine in kachestvam cows in combination with protective leukemia viruses of cattle (See. "Veterinary newspaper. - 8. - 2001. - S. 5).

Developed by the Institute of VIEW anti-leukemia activities as such do not provide treatment of sick cattle and don't get feleciana, and is aimed at early identification of infected and diseased animals and their isolation from the herd.

There is a method of treating leukemia cattle by injection intramuscularly arsenic, for example, in the form of tablerowcolor solution in an amount of 10 ml per day in combination with enter in the course of the day drugs: potassium iodide in a quantity of 0.5 g of cobalt chloride in an amount of 10 mg of iron sulfate in the amount of 2 grams of copper sulfate in the amount of 0.5 g per 30 days (Cm. "Internal non-infectious diseases of farm animals". - M.: Publishing house "spike". - 1967. - S. 341).

The disadvantage of this method is that it is not reached full feleciana animal, as the positive effect of ARSENICAL drugs based on their inhibitory effect on leukemia metaplasia in the organs (spleen, liver, bone marrow and in the lymph nodes, i.e., the drug arsenic suppresses bone marrow leucopoiesis and simultaneously stimulates the production of red blood cells, normalizing blood picture animals, providing the offensive dlitelyny on immunoprophylaxis of leukemia by injection of vaccines, obtained on the basis of membrane antigens of cultured blood lymphocytes of patients with leukemia cows in combination with protective leukemia viruses of cattle or vaccine, obtained with the use of vaccinia virus (See. "Veterinary newspaper. - 8. - 2001. - S. 5).

The disadvantage of this method is that the method is not tested in production conditions, and the vaccine was only laboratory tests.

The technical result of the present invention is to develop a method for the treatment and prevention of leukemia cattle using drugs antibacterial action against the elimination of iodine deficiency with concurrent prophylactic treatment of calves with the purpose of recovery of the entire flock.

The technical result is achieved in that in the method for the prevention and treatment of leukemia in cattle, comprising the administration of a medicinal product, in addition enter iodized table salt, as well as drug use metronidazole while metronidazole and iodized table salt is administered courses once a day for 30 days every 6 months.

In addition, prophylactic introduction animals metronidazole and iodized what,25, 0,5 and 1,0; iodized table salt - 30,0, and 50,0 70,0; and 12 months of age animals impose additional sulfa drug doses, respectively, 0.5 and 1.0 mg/goal.

In addition, in this method with curative intent metronidazole is administered at a dose of 1.0 g/bird. and iodized table salt in the dose of 70-90 g/bird., in addition impose a sulfa drug at the dose of 1.0 g/bird., repeat the treatment within 2 years.

At the same time as sulfa drug use streptocid white or sulfadimezin or norsulfazol.

A comparison of the claimed technical solution with prototypes revealed distinctive from prototypes signs, therefore, these technical solutions meet the criterion of "NOVELTY."

Analysis of technical solutions showed that the claimed set of essential features are unknown in the prior art, therefore, the technical solutions meet the criterion of "INVENTIVE step".

The author, having departed from the viral origin of leukemia cattle experimentally obtained positive results in the prevention and treatment of leukemia cattle with the use of complex drugs antibacterial action, consisting of metronidazole and p is Giovanna salt), introduction when their oral nutrition. Thus, the treatment group patients and patients with leukemia for several years herds of cows from 11 goals achieved full recovery as infected and sick cows, and during rearing (flock of 17 goals) prophylactic administration of these drugs antibacterial action on the background exception of iodine deficiency received a herd free from leukemia, which is confirmed by the results of the analysis of blood serum of cows with receiving negative reactions of the immune diffusion (RID - negative).

Oral administration of drugs gives initially the elimination of leukemic factor in the most infected organ of the animal in the gastrointestinal tract and along a motion path with lymph blood leukemic factor is destroyed and in other organs and systems.

In addition, the application of the proposed method provides the cure mastitis, gynecological diseases in cattle and eliminates indigestion newborn calves.

Checking method for the treatment of cattle from leukemia was conducted on the farm "Forest", Khabarovsky Raion, Khabarovsk Krai on the herd of 11 goals, which had been under surveillance since 1997.

Re the animal for the presence (absence) of the leukemic factor before and after treatment for the period 1997-2001 placed in a table.1.

In the initial study, 1997, 1998, blood serum of cows in this herd at the reaction of the immune diffusion (RID) noted the presence in the blood of antibodies leukosis virus of cattle (REED+), which confirmed the infection of herds leukemia. To determine the stage of the disease in April 2000, the analysis was performed on the blood of animals for the presence of leukocytes and lymphocytosis (see tab. 1). The entire herd, but one of the cows was observed of leukocytes and lymphocytosis in the norm, which is also confirmed only infection herd animals and disease leukemia per cow under inv. 18, which gave a positive reaction on Hematology - high concentrations of leukocytes and increased lymphocytosis, which indicates the initial stage of the disease leukemia. In the period after calving (October 2000) at 30 days and 6 months (April 2001) within 30 days were treated herds of the proposed method as follows.

The cow herd was administered oral drugs: metronidazole (1 g per day per head in complex with sulfadimesine in the amount of 1 g per day per head. The drugs were administered into the oral cavity to the crest of the language. The treatment was performed on the full background to annoy salt in the amount of 70-90 g per head (zootechnical norm). One month after treatment (June 2001) conducted a study of the blood serum of cattle herd on the immune diffusion. The study confirmed the absence of antibodies leukosis virus of cattle (REED negative. ) in the serum of all animals of the herd, i.e., there was complete recovery of the cows in this herd from leukemia, which was also confirmed appearance of animals with the fatness of the highest category. The method of treatment of cattle from leukemia for a future prophylactic treatment of cows in the herd for two years with an interval of 6 months with the same drugs in the same dosage. One prophylactic treatment of the cow herd received in October 2001 (see table. 1). In April 2002, it is planned to re-check serum herds of cattle on the immune diffusion (RID). At the present time on circumstantial evidence: the past without pathologies calving, no mastitis, high fatness of cattle studied herds, it is possible to speak about the absence of infection leukemia treated herds of cattle.

The method of rearing cattle free from leukemia, were tested on a herd of 17 goals.

The results of observations of young cattle, including the timing of prophylactic treatment, the dosage of drugs, and cattle were held, since 1998, prophylactic treatment within 30 days drugs: metronidazole in combination with sulfadimezinom, dosage and time of treatment is shown in table.2.

Studies of blood serum on the immune diffusion (RID) conducted 05.05.99, 11 heads of young cattle after one preventive treatment (inv. 79, 80, 81), after two preventive treatments (for inv. 72, 76, 66, 67), after conducting three preventive treatments (inv. 55, 60) and for young animals that receive no preventive treatment (inv. 82, 87).

In addition, the study of blood serum on the immune diffusion (RID) for the remaining heads of young cattle held 06.06.2001, after the three preventive treatments (inv. 104, 105, 106), after two preventive treatments (inv. 110, 111, 112). The analysis of blood serum of all heads of young gave REED - negative, which indicates the absence of infection in the herd of young leukemia, which is confirmed also by the analysis of blood of young animals on the content of leukocytes and blood lymphocytosis, as shown in the norm of leukocytes and normal lymphocytosis.

The positive results obtained in the treatment of infected the Oia it free from leukemia with use of the drugs, make wide use of the claimed methods.

Claims

1. Method for the prevention and treatment of leukemia in cattle, comprising the administration of a medicinal product, characterized in that it further introduce iodized table salt, as well as drug use metronidazole while metronidazole and iodized table salt is administered courses once a day for 30 days every 6 months.

2. The method according to p. 1, characterized in that prophylactic introduction animals metronidazole and iodized salt operate from 6 months to 18 months of age in the following doses, g/bird. : metronidazole 0,25; 0,5 and 1,0; iodized salt 30,0; and 50,0 70,0; and 12 months of age animals impose additional sulfa drug doses, respectively, 0.5 and 1.0 mg/goal.

3. The method according to p. 1, characterized in that for therapeutic purposes metronidazole is administered at a dose of 1.0 g/bird. and iodized table salt at a dose of 70-90 g/bird. while additionally introducing sulfa drug at the dose of 1.0 g/bird. , repeat the treatment within 2 years.

4. The method according to p. 3, characterized in that as sulfanilate the

 

Same patents:

The invention relates to the field of medicine

The invention relates to solid Galanova forms like pills controlled release, designed to be extremely fast, and then prolonged release of one or more active substances

The invention relates to medicine, in particular to surgery, and can be used for sclerotherapy of large metastases in the liver

The invention relates to new derivatives of benzothiazole General formula (I) or its salt, where p denotes 1; X1and X2together form =O; R1denotes hydrogen, halogen, alkyl, alkoxy; R2denotes hydrogen; R3denotes a-Z4-R6, -Z13-NR7R8; Z4denotes a-Z11-C(O)-Z12-, -Z11-C(O)-O-Z12-; Z11and Z12represent a simple bond or alkylene; Z13denotes a-Z11-C(O)-Z12-; R4denotes hydrogen; R5denotes phenyl, substituted groups Z1, Z2selected from alkyl, halogen, nitro, -HE, hydroxyalkyl, -C(O)Z6, -C(O)OZ6-Z4-NZ7Z8where Z4represents a simple bond; biphenyl, substituted alkyl; naphthalenyl, which optionally can be substituted-HE; chinoline, substituted alkyl; heterocyclics; Z6denotes alkyl which may be optionally substituted by a group-Z4-NZ7Z8, morpholinium; Z7, Z8each independently represents alkyl; R6denotes alkyl optionally substituted by cyano, methoxy, phenyl, -Z4-NZ7Z8and so on; R7denotes hydrogen, alkyl; R8denotes alkyl, the long is Z4-NZ7Z8; and t

The invention relates to new derivatives of benzothiazole General formula (I) or its salt, where p denotes 1; X1and X2together form =O; R1denotes hydrogen, halogen, alkyl, alkoxy; R2denotes hydrogen; R3denotes a-Z4-R6, -Z13-NR7R8; Z4denotes a-Z11-C(O)-Z12-, -Z11-C(O)-O-Z12-; Z11and Z12represent a simple bond or alkylene; Z13denotes a-Z11-C(O)-Z12-; R4denotes hydrogen; R5denotes phenyl, substituted groups Z1, Z2selected from alkyl, halogen, nitro, -HE, hydroxyalkyl, -C(O)Z6, -C(O)OZ6-Z4-NZ7Z8where Z4represents a simple bond; biphenyl, substituted alkyl; naphthalenyl, which optionally can be substituted-HE; chinoline, substituted alkyl; heterocyclics; Z6denotes alkyl which may be optionally substituted by a group-Z4-NZ7Z8, morpholinium; Z7, Z8each independently represents alkyl; R6denotes alkyl optionally substituted by cyano, methoxy, phenyl, -Z4-NZ7Z8and so on; R7denotes hydrogen, alkyl; R8denotes alkyl, the long is Z4-NZ7Z8; and t

The invention relates to new derivatives of benzothiazole General formula (I) or its salt, where p denotes 1; X1and X2together form =O; R1denotes hydrogen, halogen, alkyl, alkoxy; R2denotes hydrogen; R3denotes a-Z4-R6, -Z13-NR7R8; Z4denotes a-Z11-C(O)-Z12-, -Z11-C(O)-O-Z12-; Z11and Z12represent a simple bond or alkylene; Z13denotes a-Z11-C(O)-Z12-; R4denotes hydrogen; R5denotes phenyl, substituted groups Z1, Z2selected from alkyl, halogen, nitro, -HE, hydroxyalkyl, -C(O)Z6, -C(O)OZ6-Z4-NZ7Z8where Z4represents a simple bond; biphenyl, substituted alkyl; naphthalenyl, which optionally can be substituted-HE; chinoline, substituted alkyl; heterocyclics; Z6denotes alkyl which may be optionally substituted by a group-Z4-NZ7Z8, morpholinium; Z7, Z8each independently represents alkyl; R6denotes alkyl optionally substituted by cyano, methoxy, phenyl, -Z4-NZ7Z8and so on; R7denotes hydrogen, alkyl; R8denotes alkyl, the long is Z4-NZ7Z8; and t

The invention relates to new derivatives of benzothiazole General formula (I) or its salt, where p denotes 1; X1and X2together form =O; R1denotes hydrogen, halogen, alkyl, alkoxy; R2denotes hydrogen; R3denotes a-Z4-R6, -Z13-NR7R8; Z4denotes a-Z11-C(O)-Z12-, -Z11-C(O)-O-Z12-; Z11and Z12represent a simple bond or alkylene; Z13denotes a-Z11-C(O)-Z12-; R4denotes hydrogen; R5denotes phenyl, substituted groups Z1, Z2selected from alkyl, halogen, nitro, -HE, hydroxyalkyl, -C(O)Z6, -C(O)OZ6-Z4-NZ7Z8where Z4represents a simple bond; biphenyl, substituted alkyl; naphthalenyl, which optionally can be substituted-HE; chinoline, substituted alkyl; heterocyclics; Z6denotes alkyl which may be optionally substituted by a group-Z4-NZ7Z8, morpholinium; Z7, Z8each independently represents alkyl; R6denotes alkyl optionally substituted by cyano, methoxy, phenyl, -Z4-NZ7Z8and so on; R7denotes hydrogen, alkyl; R8denotes alkyl, the long is Z4-NZ7Z8; and t

The invention relates to new substituted 6 and 7-aminotetrahydrofuran-carboxylic acids, method for their production and their use as medicines

The invention relates to new indole derivative of the formula I

< / BR>
where R denotes ethyl or 2,2,2-triptorelin group; Y is hydroxy or pivaloyloxy; the carbon atom marked with the symbol (R) is the carbon atom in (R)-configuration, or its pharmaceutically acceptable salts

The invention relates to novel ortho-substituted benzoylpyridine formula (1), where R(1) denotes H, halogen, Xand-(CH2)b-(CF2)with-CF3, a, b, C denote the zero, one of the two substituents R(2) and R(3) denotes hydroxyl, and the other of the substituents R(2) and R(3) is R(1), R(4) denotes a1-C4-alkyl, halogen, (CH2)n-(CF2)o-CF3n, mean zero, and their pharmaceutically acceptable salts

FIELD: medicine.

SUBSTANCE: method involves carrying out hernia removal in intralaminar way. Posterior longitudinal ligament defect is covered with Tacho-Comb plate after having done disk cavity curettage. Subcutaneous fat fragment on feeding pedicle is brought to dorsal surface of radix and dural sac.

EFFECT: enhanced effectiveness of treatment; reduced risk of traumatic complications.

1 dwg

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: method involves intravenously administering 0.1-1% aqueous solution of khlorin, selected from group containing photolon, radachlorine or photoditazine at a dose of 0.2-0.5 mg/kg or 0.2-1% aqueous solution of porphyrin like photogem at a dose of 0.2-1 mg/kg. Laser irradiation of blood is carried out 5-15 min later after beginning photosensitizer injection into cubital vein of one arm via laser light guide set in advance in the cubital vein of the other arm during 10-40 min at wavelength of 661-666 nm and power of 20-50 mW one session per day during 3-10 days with the aqueous solution of khlorin used as the photosensitizer, or laser irradiation of blood with wavelength equal to 630-633 nm during 10-45 min with power of 20-50 mW one session per day with the aqueous solution of porphyrin used as the photosensitizer. Repeated intravenous administration of photosensitizer is carried out 1-3 months later combined with repeated laser irradiation of blood.

EFFECT: reduced risk of tumor cells dissemination and metastasis development.

2 cl

FIELD: medicine, narcology.

SUBSTANCE: one should detect satisfaction insufficiency syndrome due to performing genetic analysis by the presence of, at least, one of the genes coding the exchange of neuromediators being the constituents of human satisfaction system. One should compensate satisfaction insufficiency due to performing, at least, one complex of physical exercises. Moreover, in case of availability of pathological gene allele of dopamine D2 receptor and/or protein gene of reverse dopamine capture in patient one should apply the complex of physical exercises including those to provide sedative effect, and in case of availability of pathological gene allele of dopamine-beta-hydroxylase protein one should apply the complex of physical exercises including those that induce an activating effect. In case of availability of pathological gene allele of dopamine D2 receptor and/or protein gene of reverse dopamine capture one should apply additional food biologically active additives based upon amino acids being the precursors of neuromediators, such as taurine, D-, L-phenylalanine in combination with 5-hydroxytryptophan, hypericin and vitamin B6, and in case of pathological gene allele of dopamine-beta-hydroxylase protein one should additionally apply food biologically active additives based upon amino acids being the precursors of neuromediators, such as: taurine, tyrosine and/or dimethylaminoethanol, lecithin and group B-vitamins. The present innovation enables to take into account pathological disease mechanism.

EFFECT: higher efficiency of prophylaxis.

14 cl, 5 ex

FIELD: medicine, anesthesiology, resuscitation.

SUBSTANCE: one should perform puncturing of epidural space at Th12-L1 level. Through the lumen of puncture needle one should introduce catheter to move it cranially at the depth of 3 cm. After that one should inject 10 ml 05%-marcaine solution to perform repeated injections per 5.0 ml every 4 h during 1-8 d. The effect is achieved due to unloading minor cycle of circulation.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine, anesthesiology, resuscitation.

SUBSTANCE: one should perform puncturing of epidural space at Th12-L1 level. Through the lumen of puncture needle one should introduce catheter to move it cranially at the depth of 3 cm. After that one should inject 10 ml 05%-marcaine solution to perform repeated injections per 5.0 ml every 4 h during 1-8 d. The effect is achieved due to unloading minor cycle of circulation.

EFFECT: higher efficiency of therapy.

2 ex

Up!